Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$8.03 -0.8%	$8.52	$6.51 ▼ $13.27	$9.25M	1.63	1,050 shs	492 shs
ALXO ALX Oncology	$1.17 +13.6%	$0.57	$0.40 ▼ $2.59	$55.16M	1.14	1.60 million shs	2.86 million shs
CALC CalciMedica	$2.78 -0.4%	$2.46	$1.42 ▼ $5.97	$38.98M	1.33	50,781 shs	20,844 shs
KPTI Karyopharm Therapeutics	$6.30 +4.7%	$4.53	$3.51 ▼ $16.95	$52.20M	0.28	201,302 shs	112,192 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-2.97%	-0.37%	-1.67%	-3.26%	+5.33%
ALXO ALX Oncology	+23.80%	+57.25%	+114.63%	+122.13%	-58.80%
CALC CalciMedica	+1.45%	+6.90%	-26.19%	+55.00%	-28.46%
KPTI Karyopharm Therapeutics	-7.38%	+29.46%	+54.76%	+31.15%	-50.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.3393 of 5 stars	3.5	3.0	0.0	0.0	0.8	0.6
ALXO ALX Oncology	2.5161 of 5 stars	3.4	1.0	0.0	0.0	4.2	1.3
CALC CalciMedica	3.4148 of 5 stars	3.5	5.0	0.0	2.6	3.3	0.0
KPTI Karyopharm Therapeutics	3.8747 of 5 stars	3.4	0.0	4.6	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	273.83% Upside
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	182.05% Upside
CALC CalciMedica	3.00	Buy	$16.00	475.54% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	439.68% Upside

Current Analyst Ratings Breakdown

Latest ADXN, KPTI, ALXO, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$170.62K	49.86	N/A	N/A	$10.37 per share	0.77
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$1.20 per share	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.38	N/A	N/A	($27.55) per share	-0.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
ALXO ALX Oncology	-$134.85M	-$2.20	N/A	N/A	N/A	N/A	-115.67%	-84.82%	11/6/2025 (Estimated)
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)

Latest ADXN, KPTI, ALXO, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALXO ALX Oncology	-$0.46	-$0.49	-$0.03	-$0.49	N/A	N/A
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	3.02
ALXO ALX Oncology	0.11	4.52	4.52
CALC CalciMedica	1.39	5.45	5.45
KPTI Karyopharm Therapeutics	N/A	0.99	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
ALXO ALX Oncology	97.97%
CALC CalciMedica	N/A
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
ALXO ALX Oncology	21.00%
CALC CalciMedica	41.55%
KPTI Karyopharm Therapeutics	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
ALXO ALX Oncology	40	53.55 million	42.31 million	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable

ADXN, KPTI, ALXO, and CALC Headlines

Recent News About These Companies

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of "Moderate Buy" by Brokerages

August 21 at 3:09 AM | americanbankingnews.com

Leerink Partnrs Issues Optimistic Estimate for KPTI Earnings

August 16, 2025 | americanbankingnews.com

Robert W. Baird Has Lowered Expectations for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

August 14, 2025 | americanbankingnews.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain

August 13, 2025 | msn.com

Karyopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 12, 2025 | finanznachrichten.de

Karyopharm Therapeutics: Q2 Earnings Snapshot

August 12, 2025 | chron.com

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

August 11, 2025 | zacks.com

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

August 11, 2025 | seekingalpha.com

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 11, 2025 | prnewswire.com

Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect

August 10, 2025 | finance.yahoo.com

Earnings Outlook For Karyopharm Therapeutics

August 8, 2025 | benzinga.com

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

August 5, 2025 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 29, 2025 | zacks.com

JPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.

July 22, 2025 | gurufocus.com

HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI)

July 16, 2025 | msn.com

Karyopharm stock tumbles after disclosing failed financing talks

July 11, 2025 | investing.com

Karyopharm lays off more workers as hunt for strategic alternatives turns up short

July 11, 2025 | fiercebiotech.comF

Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway

July 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADXN, KPTI, ALXO, and CALC Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$8.02 -0.07 (-0.80%)

Closing price 03:43 PM Eastern

Extended Trading

$8.02 0.00 (0.00%)

As of 04:04 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

ALX Oncology NASDAQ:ALXO

$1.17 +0.14 (+13.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.43%)

As of 07:57 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CalciMedica NASDAQ:CALC

$2.78 -0.01 (-0.36%)

Closing price 03:58 PM Eastern

Extended Trading

$2.80 +0.02 (+0.72%)

As of 07:46 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Karyopharm Therapeutics NASDAQ:KPTI

$6.30 +0.28 (+4.65%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 +0.08 (+1.27%)

As of 07:50 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time